Sunday, July 22, 2018 8:28:01 AM
Enlightening article! Thanks for posting. It lead me to the following article which certainly helped me to understand in more simplistic terms what A2-73 hopes to address.
“Mitochondrion – much more than an energy converter
Quick look:
Mitochondrion (plur: mitochondria) – energy converter, determinator, generator (of reactive oxygen chemicals), enhancer, provider of genetic history and, controversially, an aid to boost the success rate in infertility treatment.
Mitochondria are organelles that are virtually cells within a cell. They probably originated billions of years ago when a bacterial cell was engulfed when visiting what was to become a host cell. The bacterial cell was not digested and stayed on in symbiotic relationship.
A true story of a visitor that stayed on and on……for ever. Like many visitors the guest bacterium contributes something towards its keep; the mitochondrion has certainly made sure its presence is felt. In addition to the features mentioned below mitochondria also take part in reactions concerning fatty acid metabolism, the urea cycle and the biosynthesis of the haem part of haemoglobin
Click here to view an image of mitochondria interpreted using the Gridpoint cross-hairs device
Mitochondria: the energy converters
Mitochondria, using oxygen available within the cell convert chemical energy from food in the cell to energy in a form usable to the host cell. The process is called oxidative phosphorylation and it happens inside mitochondria. In the matrix of mitochondria the reactions known as the citric acid or Krebs cycle produce a chemical called NADH. NADH is then used by enzymes embedded in the mitochondrial inner membrane to generate adenosine triphosphate (ATP). In ATP the energy is stored in the form of chemical bonds. These bonds can be opened and the energy redeemed.”
“Mitochondria: determinators
Recent research indicates that in addition to converting energy mitochondria play quite a large part in determining when a cell will die by ordinary cell death (necrosis) or programmed cell death (apoptosis). In apoptosis the mitochondrion releases a chemical, cytochrome c, and this can trigger programmed cell death (apoptosis).
https://bscb.org/learning-resources/softcell-e-learning/mitochondrion-much-more-than-an-energy-converter/
Highly recommend reading the above link in it entirety and as it helped me understand the following as it relates to A2-73 research.
“Among its conclusions, the report reveals that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer's disease (AD). Mitochondrial damages have been consistently reported as an early cause of AD and appear before amyloid-beta plaques and memory decline in Alzheimer's patients and transgenic mice. Thus, by preserving mitochondrial functionality and reducing other key AD hallmarks, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.”
https://www.google.com/amp/s/www.cnbc.com/amp/2015/02/25/globe-newswire-anavex-2-73-could-prevent-alzheimers-disease-in-addition-to-modifying-and-treating-symptoms.html
At least validation of the sigma1 approach if not A2-73 in particular.
“We therefore evaluated the effect of ANAVEX2-73 and PRE-084, a reference s1R agonist, on preservation of mitochondrial integrity in Aß25-35-injected mice. In isolated mitochondria from hippocampus preparations of Aß25-35 injected animals, we measured respiration rates, complex activities, lipid peroxidation, Bax/Bcl-2 ratios and cytochrome c release into the cytosol. Five days after Aß25-35 injection, mitochondrial respiration in mouse hippocampus was altered. ANAVEX2-73 (0.01-1 mg/kg IP) restored normal respiration and PRE-084 (0.5-1 mg/kg IP) increased respiration rates. Both compounds prevented Aß25-35-induced increases in lipid peroxidation levels, Bax/Bcl-2 ratio and cytochrome c release into the cytosol, all indicators of increased toxicity. ANAVEX2-73 and PRE-084 efficiently prevented the mitochondrial respiratory dysfunction and resulting oxidative stress and apoptosis. The s1R, targeted selectively or non-selectively, therefore appears as a valuable target for protection against mitochondrial damages in AD.”
https://www.ncbi.nlm.nih.gov/m/pubmed/25653589/
On a tangential note.
If mitochondria are evolved from bacterium, then perhaps our systemic use of broad spectrum antibiotics is playing a role in Alzheimer’s. Just a thought.
(Bolding mine)
“Mitochondrion – much more than an energy converter
Quick look:
Mitochondrion (plur: mitochondria) – energy converter, determinator, generator (of reactive oxygen chemicals), enhancer, provider of genetic history and, controversially, an aid to boost the success rate in infertility treatment.
Mitochondria are organelles that are virtually cells within a cell. They probably originated billions of years ago when a bacterial cell was engulfed when visiting what was to become a host cell. The bacterial cell was not digested and stayed on in symbiotic relationship.
A true story of a visitor that stayed on and on……for ever. Like many visitors the guest bacterium contributes something towards its keep; the mitochondrion has certainly made sure its presence is felt. In addition to the features mentioned below mitochondria also take part in reactions concerning fatty acid metabolism, the urea cycle and the biosynthesis of the haem part of haemoglobin
Click here to view an image of mitochondria interpreted using the Gridpoint cross-hairs device
Mitochondria: the energy converters
Mitochondria, using oxygen available within the cell convert chemical energy from food in the cell to energy in a form usable to the host cell. The process is called oxidative phosphorylation and it happens inside mitochondria. In the matrix of mitochondria the reactions known as the citric acid or Krebs cycle produce a chemical called NADH. NADH is then used by enzymes embedded in the mitochondrial inner membrane to generate adenosine triphosphate (ATP). In ATP the energy is stored in the form of chemical bonds. These bonds can be opened and the energy redeemed.”
“Mitochondria: determinators
Recent research indicates that in addition to converting energy mitochondria play quite a large part in determining when a cell will die by ordinary cell death (necrosis) or programmed cell death (apoptosis). In apoptosis the mitochondrion releases a chemical, cytochrome c, and this can trigger programmed cell death (apoptosis).
https://bscb.org/learning-resources/softcell-e-learning/mitochondrion-much-more-than-an-energy-converter/
Highly recommend reading the above link in it entirety and as it helped me understand the following as it relates to A2-73 research.
“Among its conclusions, the report reveals that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer's disease (AD). Mitochondrial damages have been consistently reported as an early cause of AD and appear before amyloid-beta plaques and memory decline in Alzheimer's patients and transgenic mice. Thus, by preserving mitochondrial functionality and reducing other key AD hallmarks, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.”
https://www.google.com/amp/s/www.cnbc.com/amp/2015/02/25/globe-newswire-anavex-2-73-could-prevent-alzheimers-disease-in-addition-to-modifying-and-treating-symptoms.html
At least validation of the sigma1 approach if not A2-73 in particular.
“We therefore evaluated the effect of ANAVEX2-73 and PRE-084, a reference s1R agonist, on preservation of mitochondrial integrity in Aß25-35-injected mice. In isolated mitochondria from hippocampus preparations of Aß25-35 injected animals, we measured respiration rates, complex activities, lipid peroxidation, Bax/Bcl-2 ratios and cytochrome c release into the cytosol. Five days after Aß25-35 injection, mitochondrial respiration in mouse hippocampus was altered. ANAVEX2-73 (0.01-1 mg/kg IP) restored normal respiration and PRE-084 (0.5-1 mg/kg IP) increased respiration rates. Both compounds prevented Aß25-35-induced increases in lipid peroxidation levels, Bax/Bcl-2 ratio and cytochrome c release into the cytosol, all indicators of increased toxicity. ANAVEX2-73 and PRE-084 efficiently prevented the mitochondrial respiratory dysfunction and resulting oxidative stress and apoptosis. The s1R, targeted selectively or non-selectively, therefore appears as a valuable target for protection against mitochondrial damages in AD.”
https://www.ncbi.nlm.nih.gov/m/pubmed/25653589/
On a tangential note.
If mitochondria are evolved from bacterium, then perhaps our systemic use of broad spectrum antibiotics is playing a role in Alzheimer’s. Just a thought.
(Bolding mine)
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

